Agios posts Phase 2 tebapivat sickle cell trial update press release - AGIO News | RalliesAgios posts Phase 2 tebapivat sickle cell trial update press release
A
AGIO• Phase 2 tebapivat sickle cell data
- Agios posted Phase 2 topline data for tebapivat in sickle cell disease, citing no differentiated profile to justify continued development.
- Hemoglobin response met 43.8% at 2.5 mg, 47.1% at 5 mg, 29.4% at 7.5 mg; placebo was 33.3%.
- Mitapivat sickle cell sNDA remains under FDA Priority Review; PDUFA goal date is Nov. 1, 2026.
